Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer

NCT03592641 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

NIH

Sponsor class

Stopped Inadequate accrual rate

Conditions

Colorectal Carcinoma
Metastatic Colon Adenocarcinoma
Metastatic Rectal Adenocarcinoma
Stage III Colon Cancer AJCC v8
Stage III Rectal Cancer AJCC v8
Stage IIIA Colon Cancer AJCC v8
Stage IIIA Rectal Cancer AJCC v8
Stage IIIB Colon Cancer AJCC v8
Stage IIIB Rectal Cancer AJCC v8
Stage IIIC Colon Cancer AJCC v8
Stage IIIC Rectal Cancer AJCC v8
Stage IV Colon Cancer AJCC v8
Stage IV Rectal Cancer AJCC v8
Stage IVA Colon Cancer AJCC v8
Stage IVA Rectal Cancer AJCC v8
Stage IVB Colon Cancer AJCC v8
Stage IVB Rectal Cancer AJCC v8
Stage IVC Colon Cancer AJCC v8
Stage IVC Rectal Cancer AJCC v8
Unresectable Colon Adenocarcinoma
Unresectable Rectal Adenocarcinoma

Interventions

DRUG: Savolitinib

Sponsor

National Cancer Institute (NCI)